The involvement of 5-HT1A serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia;Udział receptorów serotoninowych 5-HT1A w patofizjologii i farmakoterapii schizofrenii

Psychiatria Polska

Volumn 34, Issue 4, 2000, Pages 607-621

  Mackowiak M ^a   Czyrak, A ^a   Wedzony K ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; DIZOCILPINE; DOPAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR;

ARTICLE; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; FRONTAL CORTEX; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PREFRONTAL CORTEX; RECEPTOR DENSITY; SCHIZOPHRENIA; STRESS;

ANIMALS; ANTIPSYCHOTIC AGENTS; FRONTAL LOBE; HUMANS; N-METHYLASPARTATE; PREFRONTAL CORTEX; RATS; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 0034510835     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
2. Anatomy, cell biology, and plasticity of the serotonergic system. Neuropsychopharmacological implications for the actions of psychotropic drugs
3. Schizophrenia: Brain structure and function
4. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia
5. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia
6. Functional magnetic resonance imaging brain mapping in psychiatry: Methodological issues illustrated in a study of working memory in schizophrenia
7. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease
8. Schizophrenia: Introduction and overview
9. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain - A combined in situ hybridisation/in vitro receptor autoradiographic study
10. Schizophrenia - A brain disease? A critical review of structural and functional cerebral abnormality in the disorder
11. Cellular localization of serotonin 1A, 1B and uptake sites in cingulate cortex of the rat
12. Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia
13. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: Implications for schizophrenia and Parkinson's disease
14. NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: Evidence for modulation by a 5-HT1A antagonist
15. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: Effects of diazepam
16. 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin
17. Dopaminergic mechanisms in the pathogenesis of schizophrenia
18. The 5-HT2A (serotonin2A) receptor gene in the aetiology, pathophysiology and pharmacotherapy of schizophrenia
19. Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia
20. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites
21. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
22. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: Behavioral and neurochemical evidence
23. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle
24. Drug treatment of the negative symptoms of schizophrenia
25. Dopamine, the prefrontal cortex and schizophrenia
26. Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists
27. 1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex
28. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity
29. The behavioural effects of MK-801 in rats: Involvement of dopaminergic, serotonergic and noradrenergic systems
30. Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats
31. 1A antagonist WAY 100135 on behavioural and biochemical effects of MK-801
32. Locomotor hyperactivity induced by MK-801 in rats
33. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat
34. Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: An in situ hybridization-receptor autoradiographic analysis
35. Regulation of glutamate release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus
36. Regulation of GABA release via NMDA and 5-HT1A receptors in guinea pig dentate gyrus
37. Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites
38. Phencyclidine and auditory sensory gating in the hippocampus of the rat
39. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
40. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia
41. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
42. Regional variations in the pharmacology of NMDA receptor channel blockers: Implications for therapeutic potential
43. 5-HT1a agonist +/- 8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine
44. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation
45. Phencyclidine-induced stereotyped behaviour and social isolation in the rat: A possible animal model of schizophrenia
46. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication
47. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine
48. Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats
49. Single doses of MK-801, a non-competitive antagonist of NMDA receptors, increase the number of 5-HT1A serotonin receptors in the rat brain
50. Ipsapirone enhances the dopamine outflow via 5-HT1A, receptors in the rat prefrontal cortex
51. Evidence that conditioned stress enhances outflow of dopamine in rat prefrontal cortex: A search for the influence of diazepam and 5-HT1A agonists
52. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex
53. Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats
54. Behavioral effects of dizocilpine are sensitive to modulation of serotonergic neurotransmission